Prediction of Drug-drug Interactions

Prediction of Drug-drug Interactions

Predicting Drug-drug Interactions Using the Simcyp Simulator Unmanageable drug-drug interactions have led to the withdrawal of numerous drugs from the market. Many of these interactions involve inhibition and, to a lesser extent, induction of drug metabolizing enzymes. Consequently, the ability to predict metabolically-based drug-drug interactions (mDDI) early in the drug development process is essential. The sophisticated […]

Read More
Topics:

Simcyp Pediatric

Model Pharmacokinetics in Virtual Children Simcyp® Pediatric is a module within the Simcyp Population-based Simulator, which is licensed to members of the Simcyp Consortium of leading pharmaceutical and biotechnology companies. It allows pharmacokinetic behavior to be modeled in neonates, infants and children. This provides valuable information relevant to first-time dosing decisions and the design of […]

Read More
Topics:

Cardiac Safety Simulator

Addressing Drug Candidates’ Cardiotoxicity Risk The Cardiac Safety SimulatorTM (CSS) is a software solution that integrates physiologically-based pharmacokinetic PBPK modeling and simulation with a cardiomyocyte model to predict the cardiac effects of drugs. It is a standalone product and can be purchased independently of Certara’s Simcyp® Simulator. Drug-induced cardiovascular adverse events are one of the […]

Read More
Topics:

Simcyp PBPK Modeling and Simulation

Simcyp.com has moved to Certara.com The Simcyp’s Population-based Simulator, combined with our suite of software products and scientific consulting services has provided significant drug development advantages to our clients. The Simcyp Simulator includes extensive demographic, physiologic and genomic databases which include algorithms which account for patient variability. This enables the user to predict drug behavior in virtual […]

Read More
Topics:
Learn More LinkedIn Twitter Facebook Email Subscribe to the Blog